May 16th 2025
First-line cemiplimab showed improved survival vs chemotherapy in advanced NSCLC with brain metastases and PD-L1 ≥50% in EMPOWER-Lung 1.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Exploring Outcomes From TROPION-Lung01 Presented at WCLC 2024
September 19th 2024Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.
Watch
HARMONi-02 Reveals Key Lung Cancer Insights at WCLC 2024
September 19th 2024Panelists discuss how the HARMONi-02 trial presented at World Conference on Lung Cancer 2024 revealed key lung cancer insights, focusing on progression-free survival and immune-related response criteria end points, while emphasizing the trial’s significance for specific patient subgroups.
Watch
WCLC 2024: Analyzing SKIPPirr Data Outcomes for Lung Cancer Advancements
September 19th 2024Panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies.
Watch
Highlights from WCLC 2024: CheckMate -77T vs. CheckMate -816
September 19th 2024Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, potentially revolutionizing treatment strategies and enhancing long-term survival rates for patients with lung cancer.
Watch
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
Adagrasib Outperforms Docetaxel for Pretreated KRAS G12C-Mutant Non–Small Cell Lung Cancer
September 15th 2024Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.
Read More
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
Early Zidesamtinib Data Appear Promising for ROS1+ NSCLC
September 14th 2024The novel ROS1 inhibitor zidesamtinib demonstrated promising early activity in heavily pretreated patients with advanced ROS1-fusion-positive non–small cell lung cancer, including in those treated with other next-generation TKIs.
Read More
FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC
August 27th 2024New data on zongertinib for HER2-positive non–small cell lung cancer will be presented at the IASLC 2024 World Conference on Lung Cancer, shedding light on its potential as a novel treatment option for this patient population.
Read More
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
August 20th 2024Lazertinib and amivantamab as a first-line treatment for patients with locally advanced or metastatic non–small cell lung cancer with specific EGFR mutations demonstrated superior efficacy compared with standard treatment.
Read More
FDA Lifts Partial Clinical Hold on Phase 1 YL202 Trial in NSCLC and Breast Cancer
August 19th 2024The FDA has lifted the partial clinical hold on the phase 1 YL202-INT-101-01 trial, allowing enrollment to resume in the US for patients with advanced NSCLC harboring EGFR mutations and HR-positive/HER2-negative breast cancer.
Read More